INmune Bio (INMB) IPO Opens at $8.44

INmune Bio's (NASDAQ: INMB) IPO opened at $8.44 after pricing at $8.

INmune Bio is a clinical-stage biotechnology company developing therapies targeting the innate immune system in cancer. INmune Bio is developing two products platforms that reengineer the patient’s innate immune system’s response to their cancer, INKmune and INB03. INKmune is a Natural Killer (NK) cell therapeutic that primes the patient’s NK cells to attack developing disease. INB03 inhibits myeloid derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD1 checkpoint inhibitors. INmune Bio’s product platforms target residual disease and utilize a precision medicine approach for treatment of a wide variety of hematologic malignancies and solid tumors.

You May Also Be Interested In

• OPay prices IPO at $19 per share on the New York Stock Exchange
• PodcastOne CFO to depart, company begins successor search
• Thomas McInerney to resign from Enact Holdings board by year-end